Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROACT 2
NCT05850091Phase 4Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rosuvastatin and colchicine in coronary artery disease (CAD) (4 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Change in total non-calcified plaque volume at 1 year. Started Dec 2023; status: active, not recruiting.
02
Drugs
rosuvastatincolchicine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05850091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850091.